Breast cancer is the second leading cause of cancer death in women. About 1 in 8 women in the U.S. will develop invasive breast cancer during her lifetime. Our lab is interested in understanding altered signaling pathways that lead to breast cancer initiation and progression. Identifying and understanding these pathways will lead to development of novel therapies. Recently our lab has become interested in understanding how signaling pathways regulate metabolic reprogramming in cancer cells.
Every year approximately 200,000 new cases of breast cancer are diagnosed, and 40,000 women are expected to die from this disease in the U.S. alone. Our lab's long-term goal is to identify novel therapeutic targets for treatment of breast cancer. We are trying to understand alterations in cellular signaling pathways between normal and cancer cells and exploit these differences for possible therapeutic gain.
IN THE MEDIA
Congratulations to Dr. Reginato, recipient of the 2022-2023 STAR Scholar Outstanding Mentor of the Year Award. Read more.
"Teaming Up to Fight Brain Tumors"
College of Medicine Alumni Magazine (Fall/Winter 2016)
Reginato Lab Receives 2023 PA Breast Cancer Coalition Grant
Back to Top